The natural history of untreated muscle‐invasive bladder cancer

Alberto Martini(The University of Texas MD Anderson Cancer Center), Peter Wiklund(Unknown), John P. Sfakianos(Mount Sinai Medical Center), Ashkan Mortezavi(Karolinska Institutet), Reza Mehrazin(Icahn School of Medicine at Mount Sinai), Matthew D. Galsky(Icahn School of Medicine at Mount Sinai), A. Abolfazl Hosseini(Karolinska Institutet), Gunnar Steineck(University of Gothenburg), Lotta Renström‐Koskela(Karolinska Institutet), Lars Egevad(Karolinska Institutet), Ugo Giovanni Falagario(Ospedali Riuniti di Foggia)
British Journal of Urology
July 16, 2019
10.1111/bju.14872
Cited by 130

Related Papers

Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial
|The Lancet|2016|3.7k
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
|The Lancet|2016|2.2k
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
|The Lancet|2020|1.8k
Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial
|The Lancet Oncology|2017|1.8k
Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial
|The Lancet|2020|786